OLK Olink Holding AB ADRs
Olink Holding AB (publ) provides products and services for human protein biomarker discovery worldwide. Its Olink Explore product line include protein biomarker assays primarily for cardiovascular and metabolic diseases, oncology, neurology, and inflammation; Olink Target product line comprise human protein biomarkers for monitoring immune system and downstream applications in clinical trials; and Olink Focus product line consists of custom developed solutions for customers that have identified a small number of proteins of interest, or a protein signature. The company also offers Olink Signature Q100, a qPCR readout platform for proximity extension assay; Olink NPX Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of normalized protein expression (NPX) data. In addition, it provides Olink Analysis service comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. The company was founded in 2016 and is headquartered in Uppsala, Sweden. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$22.32 -0.48 (-2.11%)
As of 03/27/2023 14:02:02 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Mid cap
GICS sector: Health Care
Industry: Diagnostics & Research
Index country: Sweden
Country of incorporation:
IPO date: 03/25/2021
Outstanding shares: 124,108,371
Average volume: 93,292
Market cap: $2,737,830,664
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%